SE0104203L - Farmaceutiska formuleringar och metoder innefattande intranasalt morfin - Google Patents

Farmaceutiska formuleringar och metoder innefattande intranasalt morfin

Info

Publication number
SE0104203L
SE0104203L SE0104203A SE0104203A SE0104203L SE 0104203 L SE0104203 L SE 0104203L SE 0104203 A SE0104203 A SE 0104203A SE 0104203 A SE0104203 A SE 0104203A SE 0104203 L SE0104203 L SE 0104203L
Authority
SE
Sweden
Prior art keywords
morphine
pharmaceutical formulations
methods involving
pharmaceutically acceptable
intranasal morphine
Prior art date
Application number
SE0104203A
Other languages
Unknown language ( )
English (en)
Other versions
SE0104203D0 (sv
Inventor
Raja G Achari
Charanjit R Behl
Jorge C Demeireles
Ramneik Dua
Anthoney P Sileno
Vincent D Romeo
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of SE0104203L publication Critical patent/SE0104203L/sv
Publication of SE0104203D0 publication Critical patent/SE0104203D0/sv

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE0104203A 1999-06-16 2001-12-14 Farmaceutiska formuleringar och metoder innefattande intranasalt morfin SE0104203D0 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16
PCT/US2000/014157 WO2000076506A1 (en) 1999-06-16 2000-05-23 Pharmaceutical formulations and methods comprising intranasal morphine

Publications (2)

Publication Number Publication Date
SE0104203L true SE0104203L (sv) 2001-12-14
SE0104203D0 SE0104203D0 (sv) 2001-12-14

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104203A SE0104203D0 (sv) 1999-06-16 2001-12-14 Farmaceutiska formuleringar och metoder innefattande intranasalt morfin

Country Status (30)

Country Link
US (1) US6677346B1 (sv)
EP (2) EP1419774A1 (sv)
JP (1) JP2003501467A (sv)
KR (1) KR20020016831A (sv)
AU (1) AU774175B2 (sv)
BG (1) BG106221A (sv)
BR (1) BR0012082A (sv)
CA (1) CA2374877C (sv)
CZ (1) CZ20014399A3 (sv)
DE (1) DE10084709T1 (sv)
DK (1) DK200101859A (sv)
EE (1) EE200100677A (sv)
ES (1) ES2197792B1 (sv)
FI (1) FI20012462A (sv)
GB (1) GB2367005A (sv)
HR (1) HRP20010926A2 (sv)
HU (1) HUP0201856A3 (sv)
IS (1) IS6202A (sv)
LT (1) LT4976B (sv)
LU (1) LU90859B1 (sv)
LV (1) LV12859B (sv)
MX (1) MXPA01012879A (sv)
NO (1) NO20015931L (sv)
NZ (1) NZ515783A (sv)
PL (1) PL352556A1 (sv)
SE (1) SE0104203D0 (sv)
SI (1) SI20850A (sv)
SK (1) SK18172001A3 (sv)
TR (1) TR200103613T2 (sv)
WO (1) WO2000076506A1 (sv)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
EP1328214A4 (en) * 2000-09-20 2009-07-29 Shahinian Lee Jr NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
KR20070104884A (ko) 2004-11-24 2007-10-29 메드포인트 헬쓰케어 인크. 아젤라스틴을 포함하는 조성물 및 이의 사용 방법
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
US20070093420A1 (en) 2005-08-26 2007-04-26 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
BRPI0720434A2 (pt) * 2006-12-22 2014-01-07 Sigma Tau Ind Farmaceuti Gel útil para liberação de fármacos oftálmicos
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
MY194947A (en) 2011-05-13 2022-12-27 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
US20150231130A1 (en) 2012-07-26 2015-08-20 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
WO2015095389A1 (en) * 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
AU2016205225A1 (en) 2015-01-07 2017-08-17 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
AU2017345767A1 (en) * 2016-10-21 2019-05-16 Somniferum Labs LLC Apparatus for controlled delivery of opioid and other medications
KR102660711B1 (ko) * 2017-10-20 2024-04-26 키에시 파르마슈티시 엣스. 피. 에이. 활성 성분으로서 오피오이드 수용체 효능제를 포함하는 약제학적 제제, 그의 제조 방법 및 치료적 사용
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス,エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
EP0865789B1 (en) * 1993-03-26 2005-03-16 Franciscus Wilhelmus Henricus Maria Merkus Pharmaceutical compositions for intranasal administration of dihydroergotamine
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
CA2266898A1 (en) * 1996-09-27 1998-04-02 Nastech Pharmaceutical Co., Inc. Intranasal formulations for promoting sleep and method of using the same

Also Published As

Publication number Publication date
CA2374877C (en) 2004-04-13
NZ515783A (en) 2004-05-28
PL352556A1 (en) 2003-08-25
TR200103613T2 (tr) 2004-08-23
US6677346B1 (en) 2004-01-13
GB0128383D0 (en) 2002-01-16
ES2197792B1 (es) 2005-05-01
KR20020016831A (ko) 2002-03-06
NO20015931L (no) 2002-02-08
EE200100677A (et) 2003-02-17
EP1419774A1 (en) 2004-05-19
MXPA01012879A (es) 2003-06-24
CZ20014399A3 (cs) 2002-06-12
SI20850A (sl) 2002-10-31
JP2003501467A (ja) 2003-01-14
AU5156100A (en) 2001-01-02
SE0104203D0 (sv) 2001-12-14
HUP0201856A3 (en) 2004-12-28
GB2367005A (en) 2002-03-27
IS6202A (is) 2001-12-14
HUP0201856A1 (en) 2002-09-28
SK18172001A3 (sk) 2002-07-02
LT2001119A (en) 2002-07-25
BR0012082A (pt) 2002-05-07
LT4976B (lt) 2002-12-30
AU774175B2 (en) 2004-06-17
EP1183027A4 (en) 2003-02-05
LV12859B (en) 2002-12-20
BG106221A (en) 2002-08-30
FI20012462A (sv) 2002-01-16
HRP20010926A2 (en) 2003-04-30
CA2374877A1 (en) 2000-12-21
NO20015931D0 (no) 2001-12-04
DE10084709T1 (de) 2002-09-26
DK200101859A (da) 2001-12-12
LU90859B1 (en) 2002-01-24
EP1183027A1 (en) 2002-03-06
ES2197792A1 (es) 2004-01-01
WO2000076506A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
SE0104203L (sv) Farmaceutiska formuleringar och metoder innefattande intranasalt morfin
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
DK1341542T3 (da) Indanylderivater til behandling af luftvejssygdomme
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
ATE431738T1 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
ITMI912024A1 (it) Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
GB9902689D0 (en) Organic compounds
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
DK1156790T3 (da) Kombinationer af formoterol og motetason furat
PL312683A1 (en) Pharmaceutical solutions free of organic salts for nasal administration
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
EE200300555A (et) Morfiini sisaldav farmatseutiline preparaat ninasiseseks manustamiseks ning meetod valuvaigistava või tuimastava reaktsiooni esilekutsumiseks imetajal

Legal Events

Date Code Title Description
NAV Patent application has lapsed